ストックスクリーナーアプリを入手
3.25
2.30%
0.07
前日終値:
$3.18
開ける：
$3.22
24時間の取引高:
692.93K
Relative Volume:
0.45
時価総額：
$307.43M
収益：
$829.00M
当期純損益:
$-399.90M
株価収益率:
-0.753
EPS:
-4.3159
ネットキャッシュフロー:
$-23.20M
1週間 パフォーマンス:
+13.74%
1か月 パフォーマンス:
-44.49%
6か月 パフォーマンス:
-36.46%
1年 パフォーマンス:
-46.67%
1日の値動き範囲:
$3.18
$3.28
1週間の範囲:
$2.74
$3.28
52週間の値動き範囲:
$2.74
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, NTRA, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.255 | 514.74M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
587.37 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.76 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
588.48 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
318.83 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
145.13 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. - Business Insider
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
MYGN|Myriad Genetics Inc|Price:5.610|Chg%:-0.090 - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $6.14, Implies 8% Upside - TradingView
Myriad Genetics Inc (MYGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
3 Reasons MYGN is Risky and 1 Stock to Buy Instead - Yahoo Finance
Myriad Genetics stock trades sideways as investors digest recent revenue growth and precision oncolo - Ad-hoc-news.de
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 - The Manila Times
Myriad Genetics to Hold Second Quarter 2026 Earnings Conference Call on July 30 - Quiver Quantitative
AWHL vs. MYGN: Which women's health diagnostics stock is better now? - MSN
Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen - Clinical Lab Products
Myriad Genetics launches prenatal genetic screening test By Investing.com - Investing.com Nigeria
Myriad Genetics launches prenatal genetic screening test - Investing.com
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen - The Manila Times
Myriad's one-draw test runs four prenatal screens at 8 weeks - Stock Titan
Burning Rock and Myriad Announce Global Strategic Technology Licensing Partnership to Expand HRD Testing Worldwide - EIN News
ETFs Investing in Myriad Genetics, Inc. Stocks - TradingView
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now? - The Globe and Mail
MYGN Stock Price, Quote & Chart - ChartMill
Myriad Genetics reports FirstGene prenatal screen achieves over 98 percent sensitivity and 99 percent specificity - Traders Union
Is This the Right Time to Hold MYGN Stock in Your Portfolio? - Yahoo Finance
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - qz.com
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $4 - Moomoo
Myriad Genetics (MYGN) Q4 2024 earnings summary - Quartr
Myriad Genetics (MYGN) Proxy filing Summary - Quartr
AI upgrade boosts Prolaris Test predictive power at Myriad Genetics - Traders Union
(MYGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Myriad Genetics (MYGN) Surges 3.5%: Approaching Resistance at $6.51ADD Alert - dars.gov.et
Myriad Genetics Q1 2026 Earnings: EPS Miss Clouds Diagnostic Growth OutlookGross Profit Margin - dars.gov.et
Meta-analysis confirms Myriad's Prolaris test e... - Pluang
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer - Yahoo Finance
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
MYGNMyriad Genetics Inc Latest SEC Filings - Finviz
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Sera Prognostics adds former Myriad CEO Mark Capone to board - Stock Titan
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
大文字化:
|
ボリューム (24 時間):